Angiotensin II–HIF-1α-HILPDA Axis Drives Ferroptosis Suppression and Radioresistance in Nasopharyngeal Carcinoma

Study Background and Research Question

Nasopharyngeal carcinoma (NPC) is a prevalent epithelial malignancy in East and Southeast Asia, characterized by high rates of local recurrence and treatment resistance. Despite advances in radiotherapy, a significant proportion of NPC patients (~20%) continue to experience relapse, primarily due to the emergence of radioresistant tumor cell populations. Understanding the molecular determinants of NPC radioresistance is therefore critical for developing more effective radiosensitization strategies. The local renin-angiotensin system (RAS), particularly the role of angiotensin II (Ang II), has been implicated in NPC tumorigenesis and adaptation to hypoxic microenvironments. However, the mechanisms linking Ang II signaling to radioresistance and ferroptosis regulation remained unclear prior to this investigation.

Key Innovation from the Reference Study

The reference study (Chen et al., 2025) provides a mechanistic dissection of how local Ang II modulates radioresistance in NPC by suppressing ferroptosis—a regulated form of cell death characterized by iron-dependent lipid peroxidation. The key innovation lies in identifying a positive feedback loop involving Ang II, hypoxia-inducible factor-1 alpha (HIF-1α), and hypoxia-inducible lipid droplet-associated protein (HILPDA). This loop not only enhances HIF-1α stabilization via both MAPK pathway activation and direct AGT-HIF-1α interactions but also transcriptionally upregulates HILPDA, promoting lipid droplet accumulation and inhibiting ferroptosis. By mapping this axis, the study highlights actionable molecular targets for radiosensitization and provides a rationale for combining Ang II receptor blockade with ferroptosis induction in NPC treatment.

Methods and Experimental Design Insights

To elucidate the contribution of Ang II signaling to NPC radioresistance, the authors established radioresistant NPC cell lines (HONE1-RR and SUNE1-RR) and compared them to parental controls. Multiple molecular and cellular assays were employed, including:

• Quantitative RT-PCR, western blot, and ELISA for AGT and Ang II quantification.
• Transmission electron microscopy and biochemical assays for assessing ferroptosis markers (ferrous ion concentration, lipid oxidation).
• Bioinformatics, co-immunoprecipitation, and dual-luciferase reporter assays to dissect regulatory interactions between AGT, HIF-1α, and HILPDA.
• Colony formation and CCK8 viability assays to quantify radiosensitivity in vitro.
• In vivo validation using nude mouse NPC xenograft models subjected to radiotherapy and pharmacological treatments.
• Immunohistochemistry on NPC tissue samples to correlate biomarker expression (AGT, HIF-1α, HILPDA, GPX4) with clinical outcomes.

This comprehensive, multi-modal approach enabled the authors to link molecular events at the transcript, protein, and functional phenotypic levels.

Core Findings and Why They Matter

The study's major findings can be summarized as follows:

• Ang II Accumulation and Ferroptosis Suppression: Radioresistant NPC cells exhibited elevated local Ang II, which correlated with decreased markers of ferroptosis. Ang II blockade restored ferroptotic cell death, enhancing radiosensitivity.
• HIF-1α-HILPDA Axis and Positive Feedback: Ang II promoted HIF-1α stabilization through two parallel mechanisms: MAPK pathway activation and direct AGT-HIF-1α binding. HIF-1α, in turn, transcriptionally upregulated HILPDA, driving lipid droplet accumulation and further suppressing ferroptosis.
• Radiosensitization via Combined Targeting: Co-administration of Ang II receptor antagonists and ferroptosis inducers significantly sensitized NPC cells to radiotherapy in vitro and in xenograft models. Expression levels of AGT, HIF-1α, and HILPDA closely tracked with clinical radiosensitivity and prognosis, suggesting their utility as predictive biomarkers.

These findings substantiate the role of the local Ang II–HIF-1α–HILPDA axis as a central driver of radioresistance in NPC, offering new molecular entry points for therapeutic intervention.

Comparison with Existing Internal Articles

The mechanistic focus on MAPK pathway activation by Ang II in this study aligns with established research on MAPK/ERK pathway inhibition as a radiosensitization strategy in other tumor types. Notably, internal resources such as "SCH772984: Selective ERK1/2 Inhibitor for MAPK Pathway Research" and "SCH772984: Precision ERK1/2 Inhibitor for MAPK Pathway Research" detail how ERK1/2 inhibitors like SCH772984 disrupt downstream MAPK signaling and sensitize BRAF, NRAS, and KRAS mutant tumors to cytotoxic therapies. The present reference study extends this paradigm by implicating MAPK-driven HIF-1α stabilization in NPC radioresistance, thus further supporting the translational rationale for targeting this pathway.

Moreover, internal articles such as "Angiotensin II–HIF-1α-HILPDA Axis Suppresses Ferroptosis in NPC" provide concise summaries of the same reference study, reinforcing the significance of the identified signaling axis and its functional readouts in ferroptosis and radioresistance.

Limitations and Transferability

While the study offers robust evidence linking local Ang II signaling to ferroptosis suppression and radioresistance, several limitations merit consideration:

• The findings are derived from NPC cell lines and xenograft models, which, while informative, may not fully capture the complexity of human NPC microenvironments.
• The interplay between Ang II/AGT signaling and other pro-survival or immune pathways in NPC remains to be elucidated.
• Pharmacological interventions targeting the RAS and ferroptosis machinery must be optimized for specificity and tolerability in clinical settings.

Nevertheless, the identification of AGT, HIF-1α, and HILPDA as putative biomarkers for radiosensitivity in NPC has potential translational value, especially as part of biomarker-guided patient stratification strategies.

Protocol Parameters

• Radioresistant NPC cell establishment: Chronic fractionated irradiation of parental NPC lines (e.g., HONE1, SUNE1) with stepwise dose escalation until stable resistance phenotype is observed.
• Ferroptosis induction: Treatment with validated ferroptosis inducers at literature-backed concentrations; monitor lipid peroxidation and cell viability over 24-72 hours.
• MAPK/ERK pathway inhibition: Use of selective ERK1/2 inhibitors (such as SCH772984) at nanomolar concentrations, as recommended in prior workflows (SCH772984 workflow guide), to dissect signaling dependencies.
• Combination therapy assessment: Sequential or concurrent administration of Ang II receptor antagonists and ferroptosis inducers, with colony formation or cell proliferation assays to evaluate radiosensitization effects.

Research Support Resources

For researchers seeking to explore MAPK/ERK pathway inhibition in the context of NPC or similar tumor models, the selective ERK1/2 inhibitor SCH772984 (SKU A3805) offers nanomolar potency and high specificity, as detailed in the product information from APExBIO. This compound is suitable for both in vitro and in vivo studies focused on MAPK/ERK signaling, including settings of BRAF, NRAS, and KRAS mutation-driven cancers.

Incorporating SCH772984 into cell-based or animal model workflows can facilitate the dissection of ERK-dependent mechanisms underlying radioresistance and ferroptosis regulation. Researchers are encouraged to consult detailed protocols and product handling guidelines to maximize reproducibility and experimental insight.